共 63 条
[1]
Vogel CL(2002)Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol. 20 719-726
[2]
Cobleigh MA(2007)American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol. 25 118-145
[3]
Tripathy D(2006)Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice Am J Clin Pathol. 125 155-156
[4]
Gutheil JC(2009)The HER-2 receptor and breast cancer: 10 years of targeted anti-HER-2 therapy and personalized medicine Oncologist. 14 320-368
[5]
Harris LN(2009)Systematic review of HER2 breast cancer testing Appl Immunohistochem Mol Morphol. 17 1-7
[6]
Fehrenbacher L(2013)Comparison of dual-color in situ hybridization and fluorescence in situ hybridization in HER2 gene amplification in breast cancer Breast Cancer. 19 203-211
[7]
Wolff AC(2011)Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC Appl Immunohistochem Mol Morphol. 135 157-162
[8]
Hammond ME(2011)A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-color ISH assay Am J Clin Pathol. 59 8-17
[9]
Schwartz JN(2011)Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in situ hybridization with a novel fully automated dual-colour silver in situ hybridization method Histopathology. 3 41-800
[10]
Hagerty KL(2008)Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH) Diagn Pathol. 24 794-4858